Trial Profile

A phase II study assessing OTX-TKI in Australia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Sponsors Ocular Therapeutix

Most Recent Events

27 Sep 2022 According to an Ocular Therapeutix media release, the company plans to initiate the trial in the third quarter of 2023. The initiation will be based on the results from the phase 1 study and the companys discussion with FDA regarding potential future clinical trial requirements.
11 Feb 2022 According to an Ocular Therapeutix media release, the company plans to dose first patient in this trial shortly.
12 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com